Anchor Investment Management LLC Sells 7,000 Shares of Medtronic PLC $MDT

Anchor Investment Management LLC trimmed its holdings in shares of Medtronic PLC (NYSE:MDT) by 7.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,404 shares of the medical technology company’s stock after selling 7,000 shares during the period. Anchor Investment Management LLC’s holdings in Medtronic were worth $6,603,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of MDT. Monetary Solutions Ltd bought a new position in Medtronic in the 4th quarter valued at $27,000. IAG Wealth Partners LLC bought a new stake in shares of Medtronic during the second quarter worth $30,000. Basepoint Wealth LLC acquired a new position in shares of Medtronic during the fourth quarter valued at $32,000. Pin Oak Investment Advisors Inc. acquired a new position in shares of Medtronic during the second quarter valued at $32,000. Finally, Tucker Asset Management LLC bought a new position in Medtronic in the fourth quarter valued at about $33,000. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MDT. TD Cowen lifted their price objective on Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Sanford C. Bernstein lowered their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, June 4th. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, September 5th. Finally, Truist Financial restated a “hold” rating and issued a $99.00 price objective (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $103.92.

Medtronic Trading Down 0.1%

Shares of Medtronic stock traded down $0.07 during trading on Tuesday, hitting $93.73. 7,146,882 shares of the company were exchanged, compared to its average volume of 8,841,968. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The firm has a market capitalization of $119.89 billion, a P/E ratio of 23.09, a price-to-earnings-growth ratio of 2.13 and a beta of 0.56. The firm’s fifty day moving average price is $88.13 and its 200 day moving average price is $85.06. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is 70.94%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic advances MiniMed separation: Medtronic launched an exchange offer to split off at least 80.1% of MiniMed (Nasdaq: MMED), allowing shareholders to exchange MDT shares for MiniMed stock in a generally tax-free transaction for U.S. federal income-tax purposes. Completing the separation should let Medtronic concentrate on its cardiovascular, neuroscience and surgical businesses, while potentially unlocking value from the Diabetes unit. Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
• Positive Sentiment: AI maternal-monitoring collaboration: Medtronic is partnering with Sonus Microsystems to combine Medtronic’s vital-sign monitoring technology with Sonus’s AI-powered wearable ultrasound platform. Field studies will be funded by the Gates Foundation. The agreement supports Medtronic’s innovation profile and could create longer-term growth opportunities, though it is still at an early development stage. Sonus Microsystems and Medtronic Partner to Advance AI-Powered Maternal Health Monitoring
• Neutral Sentiment: MiniMed files registration statement: MiniMed filed an SEC Form S-4 covering the exchange of up to 225.4 million shares, or 80.1% of its outstanding stock, for validly tendered MDT shares. The filing advances the transaction but leaves investors focused on final terms, participation levels and the effect on Medtronic’s remaining ownership. MiniMed Files S-4 as Medtronic Seeks to Exit Remaining Stake
• Neutral Sentiment: Analyst sentiment remains supportive: Medtronic has an average “Moderate Buy” recommendation, indicating continued confidence in the company’s earnings outlook despite execution concerns and the portfolio transition. Medtronic Receives Average Recommendation of Moderate Buy

About Medtronic

Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.